MoneyWorks4Me

Silver Leaf acquires 10% stake in Biocon’s research arm ‘Syngene’

19 Sep 2014 Evaluate

Silver Leaf Oak (Mauritius) (Silver Leaf), an investment vehicle advised by India Value Fund Advisors (IVFA) has agreed to acquire a minority 10% stake in Biocon’s Research Services subsidiary - Syngene International (Syngene). Silver Leaf will acquire the stake from Biocon Research (BRL), a wholly owned subsidiary of Biocon at a valuation of Rs 3800 crore.

Post the completion of this transaction, Biocon and BRL will jointly hold 85.54% stake in Syngene. The above transaction is however subject to standard condition precedents including regulatory approvals.

Biocon is India’s largest and Asia's leading biotechnology company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Peers
Company Name CMP
Sun Pharma. Inds. 1842.00
Dr. Reddys Labs. 1161.00
Cipla 1365.00
Lupin 2096.00
Zydus Lifesciences 1119.50
View more..